Table 5. Single arm meta-analysis for ORR in each treatment according to PD-L1 expression subgroup.
| Treatment | ORR | 95% CI (lower) | 95% CI (upper) | 
|---|---|---|---|
| PD-L1 ≥50% | |||
| Chemo | 0.35 | 0.32 | 0.37 | 
| Nivo | 0.45 | 0.39 | 0.51 | 
| Nivo + Ipi | 0.44 | 0.38 | 0.51 | 
| Atez | 0.38 | 0.29 | 0.48 | 
| Atez + Chemo | 0.64 | 0.54 | 0.75 | 
| Pembro | 0.42 | 0.38 | 0.47 | 
| Pembro + Chemo | 0.63 | 0.56 | 0.70 | 
| PD-L 1–49% | |||
| Chemo | 0.32 | 0.29 | 0.34 | 
| Nivo | 0.36 | 0.31 | 0.41 | 
| Nivo + Ipi | 0.27 | 0.20 | 0.33 | 
| Atez + Chemo | 0.47 | 0.40 | 0.55 | 
| Pembro | 0.16 | 0.12 | 0.20 | 
| Pembro + Chemo | 0.52 | 0.46 | 0.58 | 
| PD-L1 positive | |||
| Chemo | 0.33 | 0.31 | 0.35 | 
| Nivo | 0.40 | 0.36 | 0.44 | 
| Nivo + Ipi | 0.36 | 0.31 | 0.41 | 
| Atez | 0.29 | 0.24 | 0.35 | 
| Atez + Chemo | 0.52 | 0.46 | 0.58 | 
| Pembro | 0.27 | 0.24 | 0.31 | 
| Pembro + Chemo | 0.56 | 0.50 | 0.62 | 
| PD-L1 negative | |||
| Chemo | 0.29 | 0.26 | 0.32 | 
| Nivo + Chemo | 0.38 | 0.31 | 0.45 | 
| Nivo + Ipi | 0.27 | 0.21 | 0.34 | 
| Atez + Chemo | 0.44 | 0.38 | 0.50 | 
| Pembro + Chemo | 0.47 | 0.41 | 0.54 | 
Chemo, chemotherapy; Carem + Chemo, caremlizumab plus chemotherapy; Nivo, nivolumab; Nivo + Ipi, nivolumab plus ipilimumab; Nivo + Chemo, nivolumab plus chemotherapy; Atez, atezolizumab; Atez + Chemo, atezolizumab plus chemotherapy; Pembro, pembrolizumab; Pembro + Chemo, pembrolizumab plus chemotherapy; ORR, objective response rate; PD-L1, programmed death ligand 1.